Travoprost APS Versus Xalatan® in Patient Reported Outcomes and Ocular Surface Health
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand differences in visual function-related
patient-reported outcomes between a non-BAK medication (Travoprost APS) and a BAK-preserved
medication (XALATAN®) in patients with open-angle glaucoma or ocular hypertension.